Mackenzie Financial Corp Boosts Holdings in Johnson & Johnson (NYSE:JNJ)

Mackenzie Financial Corp raised its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 2.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,652,639 shares of the company’s stock after purchasing an additional 78,805 shares during the period. Johnson & Johnson accounts for 1.0% of Mackenzie Financial Corp’s holdings, making the stock its 23rd biggest position. Mackenzie Financial Corp’s holdings in Johnson & Johnson were worth $648,380,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. RE Dickinson Investment Advisors LLC lifted its holdings in Johnson & Johnson by 163.3% during the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after purchasing an additional 98 shares in the last quarter. Advanced Research Investment Solutions LLC increased its position in Johnson & Johnson by 200.0% during the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after purchasing an additional 120 shares during the last quarter. Morton Brown Family Wealth LLC increased its position in Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after purchasing an additional 78 shares during the last quarter. Professional Financial Advisors LLC increased its position in Johnson & Johnson by 47.9% during the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after purchasing an additional 68 shares during the last quarter. Finally, Goodman Advisory Group LLC acquired a new stake in Johnson & Johnson during the second quarter worth about $39,000. 68.59% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $176.20 on Monday. The firm’s fifty day simple moving average is $167.84 and its 200-day simple moving average is $171.29. The stock has a market capitalization of $460.67 billion, a price-to-earnings ratio of 24.54, a PEG ratio of 3.49 and a beta of 0.57. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. The business had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.60 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson declared that its board has authorized a share buyback program on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 1.2% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be issued a $1.13 dividend. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.57%. Johnson & Johnson’s payout ratio is 62.95%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,410 shares of the business’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total value of $2,845,822.20. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,366,753.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Johnson & Johnson news, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kathryn E. Wengel sold 16,410 shares of the business’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at $12,366,753.62. The disclosure for this sale can be found here. In the last three months, insiders have sold 118,795 shares of company stock valued at $20,230,174. 0.35% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on JNJ shares. Barclays assumed coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective for the company. Atlantic Securities dropped their price target on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Raymond James dropped their price target on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Bank of America dropped their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Finally, Citigroup dropped their price target on shares of Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. Seven equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $181.33.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.